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Normal growth and morphogenesis of the cranial vault reflect a balance between cell proliferation in the sutures and
osteogenesis at the margins of the cranial bones. In the clinical condition craniosynostosis, the sutures fuse prematurely as
a result of precocious osteogenic differentiation and craniofacial malformation results. Mutations in several fibroblast
growth factor receptor (FGFR) genes have now been identified as being responsible for the major craniosynostotic
syndromes. We have used a grafting technique to manipulate the levels of endogenous FGF-2 ligand in embryonic chick
cranial vaults and thereby perturb morphogenesis. Implantation of beads loaded with FGF-2 did not affect normal cranial
development at physiological concentrations, although they elicited a morphogenetic response in the limb. Implantation of
beads loaded with a neutralising antibody to FGF-2 generated a concentration-dependent response. When a single bead was
implanted, the grafts grew to a massive size as a result of increased cell division in the tissue. With greater inactivation of
FGF-2 protein (two to three beads implanted), all further bone differentiation and cell proliferation was blocked. These data
further support the emerging idea that the intensity of FGF-mediated signalling determines the developmental fate of the
skeletogenic cells in the cranial vault. High and low levels correlate with differentiation and proliferation, respectively. A
balance between the two ensures normal cranial vault morphogenesis. This is consistent with the observation that several
FGFR mutations causing craniosynostosis result in constitutive activation of the receptor. © 2002 Elsevier Science (USA)
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The vertebrate skull is a modular structure consisting of
three component parts which appear to use different devel-
opmental mechanisms to specify form and pattern (Hanken
and Thorogood, 1993). The cranial vault is known to be
composed largely of neural crest-derived ectomesenchyme
(Couly et al., 1993). This neural crest lineage includes not
only the osteogenic cells of the membrane bones compris-
ing the cranial vault itself, but also the cells of the sutures
or growth zones which exist at the interfaces between the
bones. Normal morphogenesis of the cranial vault reflects a
balance between cell differentiation (into osteoblasts) at the
osteogenic front and proliferation of osteogenic precursors
within the sutures themselves. Depending on location, age,
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All righand health, sutures remain proliferative and “open” during
infancy and beyond, allowing the cranial vault to accom-
modate the growing brain, before finally closing through
bony union. Little is known about the cellular and molecu-
lar controls of sutural function and what determines
whether sutural cells operate in a proliferative or differen-
tiative (i.e., osteogenic) mode. However, the underlying
dura appears to play some, as yet undefined, role in these
events (Levine et al., 1998; Mehrara et al., 1998, 1999;
Opperman et al., 1993, 2000; Yu et al., 1997).
Precise spatiotemporal integration of the dual functions
of growth and differentiation within the sutures is essential
for normal skull morphogenesis. Premature closure of the
sutures, i.e., a cessation of growth and their bony fusion,
underlies the clinical condition of “craniosynostosis” in
which the cranial vault loses its growth potential and yet
houses a brain that continues to grow. This can arise during
fetal development or postnatally and causes dysmorphogen-
esis of the skull and face, sometimes associated withE-mail: ferretti@ich.ucl.ac.uk.
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central nervous system damage (Cohen, 1993; Reardon and
Winter, 1995). Craniosynostosis can occur in both syn-
dromic and nonsyndromic forms and affects around 1 in
2500 children (Gorlin et al., 1990). Six of the major cranio-
synostosis syndromes have now been associated with mu-
tations in the fibroblast growth factor receptors (FGFR) 1, 2,
and 3 (reviewed in Muenke and Schell, 1995; Burke et al.,
1998; Wilkie, 1997). These mutations appear to cause
ligand-independent activation of the receptor and an in-
crease in signalling.
Much less information is available on the role of FGF
ligands in the regulation of cranial skeletogenic differentia-
tion. A retrovirally mediated insertional mutation in the
intragenic region between the Fgf3 and Fgf4 genes (high
affinity ligands for FGFR2) has led to the production of the
Bulgy-eye (Bey) mouse (Carlton et al., 1998). This mutation
results in the upregulation of both FGF3 and FGF4 in the
cranial sutures, and phenotypically the Bey mouse shows
features comparable to those found in Crouzon syndrome.
There is evidence that FGF-2 may play a role in cranial
differentiation. Implantation of FGF-2-soaked beads into
the cranial sutures of mice induced ectopic expression of
osteopontin, an early marker of osteogenic differentiation
and downregulation of Fgfr2 (Iseki et al., 1997, 1999). Our
recent studies have shown that premigratory cranial neural
crest cells are capable of responding to FGF signals in vitro.
Depending on the concentration of FGF-2, neural crest cells
display not only a proliferative response but also chondro-
genic and osteogenic responses (Sarkar et al., 2001).
To extend and complement these previous studies,
we embarked on a series of experiments implanting
coated beads to manipulate endogenous levels of FGF-2 in
chick embryonic crania. We observed a dramatic and
concentration-dependent response: reducing endogenous
FGF-2 switches the skeletogenic cells of the cranial vault
from a differentiative to a proliferative mode, whereas
further inactivation (by the addition of more beads) abol-
ishes both proliferation and differentiation within the graft.
These results complement the concentration-dependent
effects of exogenous FGF-2 on cranial vault cells demon-
strated by others (Iseki et al., 1997, 1999; Sarkar et al.,
2001). Furthermore, they lend support to the claim that
mutations in FGFR genes producing craniosynostosis are
likely to result in the constitutive activation of the recep-
tors in question and a consequent upregulation of signalling
via the FGFR pathway.
FIG. 2. Implantation of FGF-2-coated beads into cranial tissue at E10, which is then grown on the CAM for 6 days, does not affect bone
(red) or cartilage (blue) differentiation. (A) Graft that received a bead soaked in 1 mg/ml FGF-2. (B) Control graft that received a bead soaked
in PBS. The cranial bones have formed correctly in the FGF-2-treated graft and, although there is some distortion; this is due to mechanical
changes and not a consequence of bead implantation. At no time were we able to induce ectopic bone formation or prevent normal bone
differentiation by implantation of FGF-2 beads at any concentration or in any location. The amount of parietal bone and cartilage seen in
the grafts depends on the caudal extent of the tissue at dissection. Arrows indicate site of bead implantation. f, frontal bone; p, parietal bone;
m, undifferentiated mesenchyme. Scale bar, 1 mm.
FIG. 1. Whole-mount skeletal preparations of normal embryonic chick heads stained for bone and cartilage at 10 (A, D), 14 (B, E), and 16 days (C, F).
Bone is stained red, cartilage blue. (A–C) Lateral views; (D–F) Ventral views. The cranial regions have been removed in (D–F) to show that large areas
of undifferentiated mesenchyme remain at 16 days. The schematic drawing in (G) depicts the arrangement of the bones and sutures at this stage of
development. f, frontal bone; p, parietal bone; m, mesenchyme. Scale bar, 2 mm.
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MATERIALS AND METHODS
Whole-Mount Skeletal Preparations
The procedure used was essentially that of Klymkowsky and
Hanken (1991). Tissues were fixed in Alcian blue 8GX (0.3 mg/ml
in acetic acid) at 4°C overnight. Excess stain was removed by
washing in 100% ethanol. Bone was subsequently stained with
Alizarin Red S solution (0.2 mg/ml in 0.5% KOH) for 1–2 h at room
temperature. Destaining was carried out first in 20% glycerol in
1% KOH, then in 50 and 80% glycerol in 1% KOH. Specimens
were stored in 100% glycerol at 4°C.
Chorioallantoic Membrane (CAM) Grafting
Fertilised chicken eggs (J.K. Needle and Co., Herts, UK) were
incubated for either 8 (hosts) or 10 days (donors) at 37.5°C in
humidified incubators (Curfew Ltd., Essex, UK). Hosts were win-
dowed at 8 days under sterile conditions as described by Hamburger
(1960). Eggs were sealed with Sellotape and returned to the incu-
bator until needed. Donor embryos were removed under aseptic
conditions and rinsed in phosphate-buffered saline (PBS) before
killing by decapitation. Heads were transferred to ice-cold medium
[alpha modification of Eagle’s minimal essential medium with
ribosides and deoxyribonucleosides (-MEM); Gibco/BRL, Paisley,
UK], and the region containing the presumptive frontal and parietal
bones, occipital cartilage, and roof of brain was dissected out.
Keeping the meninges and dura mater in place, the brain on the
ventral surface was removed prior to bead implantation and
grafting.
Bead Preparation
Heparin-coated acrylic beads (Sigma, Poole, UK) or Affi-Gel Blue
agarose beads (mesh 100–200; Bio-Rad Laboratories, Hercules, CA)
were soaked in PBS, preimmune rabbit serum, growth factor, or
antibody for at least 1 h at room temperature prior to implantation.
FGF-2 (bovine brain-derived basic FGF; R&D Systems, Abingdon,
UK) was used at concentrations of 1 and 10 mg/ml in PBS.
Polyclonal anti-FGF-2 (anti-basic FGF neutralising antibody; R&D
Systems) was used at a concentration of 10 mg/ml. This antibody
was raised against the bovine FGF-2 used in these experiments and
has been shown not to crossreact with a wide range of other growth
factors (Rizzino et al., 1988). To test the specificity of this antibody,
0.5 l of 10 mg/ml anti-FGF-2 was premixed with 2.5 l of 10
mg/ml FGF-2. Agarose beads were soaked in this solution for 1 h
prior to implantation.
Bead Implantation into Cranial Tissue
Incisions were made in the dorsal aspect of cranial tissue with
sharpened tungsten needles, and the appropriate number of beads
was inserted. The implanted tissue was then placed on the CAM of
the host embryo, dorsal side upwards. A few drops of Tyrodes
solution containing 25 U/ml penicillin G and 25 g/ml streptomy-
cin sulphate (Pen/Strep; Gibco/BRL) were added and the window
was resealed. Eggs were returned to the incubator and allowed to
develop for an additional 7 days. Healthy grafts were then cut out
from the CAM and stained for bone and cartilage as described
above.
Bead Implantation into Limb Buds
Chick embryos incubated for 4 days, until they reached stage 21
(Hamburger and Hamilton, 1951), were windowed as described
above. Using a sharpened tungsten needle, the vitelline membrane
was opened above the upper limb bud and a slit was made
approximately in the centre of the limb bud. Either heparin-coated
acrylic beads or Affi-Gel Blue agarose beads (Bio-Rad) loaded with
FGF-2, anti-FGF-2, or PBS were implanted. A few drops of Tyrodes
solution containing Pen/Strep were added and the egg was sealed
with a piece of Sellotape. Embryos were allowed to develop for an
additional 6 days. Recovered embryos were stained for bone and
cartilage as described above and skeletal pattern was assessed.
Immunohistochemistry
Tissue was fixed overnight in 4% paraformaldehyde in PBS at
4°C, washed twice in PBS, and dehydrated to 100% ethanol. CAM
grafts were decalcified in 0.5 M EDTA:PBS (1:1) at 37°C for 1–2
weeks before dehydration. Tissue was embedded in paraffin wax
(Lambwax; Raymond Lamb, London, UK) and sectioned at 6 m.
Slides were dewaxed in HistoClear (National Diagnostics, Atlanta,
GA), then rehydrated through a descending ethanol series. Anti-
gens were unmasked either by microwaving in citric acid buffer,
pH 6.0, for 10 min (proliferating cell nuclear antigen, PCNA) or by
trypsin digestion (1 mg/ml in PBS) for 30 min at 37°C (FGF-2,
FGFR1, and FGFR2). Endogenous peroxidase was blocked by incu-
bation with 3% hydrogen peroxide in PBS for 15 min. Nonspecific
binding was blocked with 1% bovine serum albumin/10% fetal calf
serum (Sigma) in PBS for 30 min. After washing, the relevant
primary antibody was applied and slides were incubated overnight
at 4°C. Antibody concentrations used were as follows: polyclonal
anti-FGF-2 (R&D Systems) at 50 g/ml; polyclonal rabbit anti-
FGFR1 (Santa Cruz Biotechnology, Santa Cruz, CA), polyclonal
rabbit anti-FGFR2 (Santa Cruz Biotechnology), and monoclonal
PCNA (Santa Cruz Biotechnology) at 1 g/ml. Preimmune serum,
either mouse (Dako, High Wycombe, UK) or rabbit (Sigma), was
used as a negative control in place of the primary antibody at the
same concentration. Excess primary antibody was removed by
washing in PBS containing 1% Triton-X. Primary antibodies were
detected by using a streptavidin biotin peroxidase system (ABC kit;
Dako) followed by application of diaminobenzidine (SIGMA FAST
DAB; Sigma). Sections were counterstained in Methyl Green before
mounting in dextropropoxyphene (BDH, Poole, UK).
Cell Counting and Statistical Analysis
To quantitatively assess the proportion of dividing cells in each
graft, positive and negative cell nuclei stained with PCNA were
counted as follows: 5 representative fields of mesenchyme were
counted from 1 section per slide, on each of 5 slides from each graft,
making a total of 25 counts per graft. Five grafts, for each of four
treatments, were assessed in this way. Equivalent fields of bone,
cartilage, and epidermis were counted in each section and used as
positive controls. For the purpose of measuring proliferation,
osteogenic cells were defined as those contained within the peri-
osteum. All counts were carried out blind. Data were analysed by
using the G-test for independence. CAM-graft surface area was
measured by taking the mean of the greatest length and the greatest
width and then converting to surface area using the formula r2.
The data were analysed by using Student’s t test. Limb size was
analysed by using Student’s t test for matched pairs.
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Whole-Mount Immunohistochemistry
The protocol was essentially that of Wheatley et al. (1993) with
some modifications. Cranial tissue was dissected and bead implan-
tation was carried out as before. Bead-implanted tissues were then
either incubated in -MEM at 37°C for up to 8 h, or alternatively
placed on the CAM as described before and incubated for 12–24 h
before fixing in 4% paraformaldehyde in PBS. Tissues were washed
in PBS before dehydrating through a methanol series and stored
overnight at 20°C. After bleaching in 6% hydrogen peroxide in
methanol for 1 h at room temperature, the tissue was then
rehydrated back through methanol to PBS. Nonspecific antibody
binding was then blocked by incubation in PBMT (PBS containing
2% nonfat milk and 0.1% Triton X-100) twice for 1 h each.
Secondary antibody (horseradish peroxidase-conjugated anti-rabbit
IgG) was diluted to 1.6 g/ml (1:500) in PBMT containing 10% fetal
calf serum, and tissues were incubated for 2 days at 4°C. Excess
secondary antibody was removed by six 1-h washes and one
overnight wash in PBMT. Prior to colour detection, tissue was
washed with PBT (PBS containing 0.1% Triton X-100) before
incubation with DAB (PBT containing 0.08% nickel chloride and
250 g/ml diaminobenzadine) in the dark for 30 min. To activate
the enzymatic reaction, hydrogen peroxide was then added to a
final concentration of 0.03%. The colour reaction was allowed to
proceed for 10 min in the dark before stopping by washing in PBT.
Tissue was postfixed in 4% paraformaldehyde in PBS overnight at
4°C before clearing through increasing concentrations of glycerol.
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA was carried out to measure the release of anti-FGF-2 from
agarose beads in solution. To prepare the anti-FGF-2 solutions to be
tested, washed agarose beads were transferred to 2-l drops of
either PBS or anti-FGF-2 at concentrations of 100 g/ml, 1 mg/ml,
or 10 mg/ml. After 1 h, either one or three beads were transferred
to 100 l of PBST (0.1% Tween 20 in PBS) in a microtube, and the
contents of the beads were allowed to diffuse out without shaking
for different times (15 min, 1 h, and 3 h). After the allotted time, 75
l of the supernatant was removed and stored at 4°C prior to assay.
Bovine FGF-2 was diluted in carbonate–bicarbonate coating buffer
(C-3041; Sigma) to a concentration of 250 ng/ml, and 50 l was
added to each well of a 96-well microtitre plate (Gibco/BRL). The
plate was incubated overnight at 4°C before washing twice with
PBST and briefly drying. Aspecific binding sites were blocked by
adding 200 l of 3% bovine serum albumin in PBS per well for 2 h
at room temperature. Excess block was removed by washing
with PBST. Serial dilutions of anti-FGF-2 in PBST (48 ng/ml to
100 g/ml) were prepared and assayed with each plate. Then, 50
l of the solution to be tested was added to each well and
allowed to bind for 2 h at room temperature. Unbound antibody
was then removed by several washes in PBST before addition of
a secondary antibody conjugated to alkaline phosphatase (1:5000
in PBST; Sigma) for 2 h at room temperature. After additional
washes, the reaction was detected by the addition of 200 l of 1
g/liter p-nitrophenylphosphate substrate (Sigma) for approxi-
mately 30 min in the dark. Optical densities of the wells were
read immediately at 410 nm on a Dynatech Elisa Plate Reader
(Becton Dickinson).
Imaging
All sections were examined with an Olympus BH2 micro-
scope, and whole-mount preparations were examined by using a
Zeiss SV-11 stereomicroscope. Images were captured electroni-
cally with a Kontron ProgRes 3012 digital camera and version
2.0 of the associated software and was stored as Adobe Photo-
shop v3.0 files.
TABLE 1
Statistical Analysis of the Effect of Ectopic FGF-2 on the Growth of Limb Elements
FGF-2 (n  14) Anti-FGF-2 (n  10) PBS (n  9)
Length Width Length Width Length Width
Humerus
Treated 2.63  0.37 0.84  0.08 4.45  0.16 0.4  0.03 4.20  0.18 0.37  0.02
Untreated 4.64  0.16 0.38  0.02 4.52  0.17 0.39  0.02 4.25  0.12 0.38  0.02
Significance P  0.001 P  0.001 ns ns ns ns
Radius
Treated 2.98  0.33 0.39  0.03 3.92  0.15 0.26  0.01 3.80  0.10 0.27  0.01
Untreated 4.1  0.12 0.3  0.01 3.98  0.14 0.26  0.01 3.84  0.09 0.27  0.01
Significance P  0.002 P  0.02 ns ns ns ns
Ulna
Treated 3.27  0.41 0.48  0.04 4.4  0.16 0.32  0.01 4.32  0.10 0.32  0.0
Untreated 4.55  0.13 0.35  0.01 4.37  0.16 0.32  0.01 4.28  0.07 0.32  0.0
Significance P  0.01 P  0.01 ns ns ns ns
Note. Treated and contralateral limb elements were measured and compared statistically by Student’s t test for matched pairs. The mean
dimensions of each limb element (in mm  standard error) are shown above and illustrate that there are significant differences between
limbs treated with FGF-2 and contralateral limbs but not between antiFGF-2 treated or PBS-treated limbs. ns, not significant.
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RESULTS
Normal Development of the Embryonic Skull
To assess the temporal and spatial formation of cranial
bones in the chick, we performed whole-mount skeletal
preparations at various stages (Fig. 1). Midway through
gestation, at 10 days of development, some cartilage has
formed in the jaw and occipital region of the skull, but
ossification has yet to commence (Figs. 1A and 1D). Four
days later, although there is some bone differentiating
within the jaw (Fig. 1B), there is relatively little in the skull
itself (Fig. 1E). There are small regions of condensing
mesenchyme around the occipital region and in the frontal
region immediately adjacent to the eye (Fig. 1E). By 16 days,
the pattern emerging (Figs. 1C and 1F, and diagram in Fig.
1G) reveals two distinct paired bones in the skull, namely
the frontal and parietal bones. In the centre of the skull,
there is still a large area of undifferentiated mesenchyme
which remains until after hatching. At this stage (16 days),
the term “suture” may be a misnomer since it refers to the
broad region of undifferentiated tissue between osteogenic
fronts. There is as yet no defined structure or cell type that
delineates where a suture will eventually form. Since at 10
days (Figs. 1A and 1D) there is little overt sign of osteogenic
differentiation, we have used this stage as a starting point
for attempts to perturb normal cranial vault development.
Exogenous FGF-2 Affects Limb but Not Cranial
Skeletogenesis
The CAM-grafting system enables cranial tissue to be
easily manipulated and then grown in a sterile vascular
environment. Grafts were implanted with either heparin-
coated acrylic beads (data not shown) or agarose beads
soaked in different concentrations of FGF-2; beads were
implanted in a variety of positions, as previous work has
shown that FGF-2 does not appear to migrate very long
distances from heparin-coated acrylic beads (Iseki et al.,
1999). Implantation of beads soaked in 1 mg/ml FGF-2 into
cranial tissue at embryonic day 10 has no effect on osteo-
genic differentiation in CAM grafts as assessed by whole-
mount skeletal staining of recovered grafts (Fig. 2). Bones
form in their correct positions and, in the graft by 16 days,
their pattern of formation is indistinguishable from that
found in control grafts or in vivo (compare Fig. 2A with Fig.
2B, and Fig. 1F with Fig. 2). Neither the type of bead used
nor its position within the graft affect cranial growth and
differentiation, suggesting that the lack of an effect is not
caused by the localisation of FGF-2 to the bead. Some minor
distortion of the bones was seen since grafting removes the
cranial vault from the tensile forces to which it is normally
exposed in situ. Nevertheless, even at the highest concen-
tration of FGF-2 used (10 mg/ml), we were unable to induce
ectopic bone formation or inhibit normal bone differentia-
tion (data not shown).
To assess the biological activity of the FGF-2-soaked beads,
we implanted them into limb buds at stage 21 (Hamburger
and Hamilton, 1951) and allowed operated embryos to develop
in ovo for an additional 6 days. Implantation of beads soaked
in 1 mg/ml FGF-2 resulted in shortened and thickened limb
elements, with the humerus, radius, and ulna particularly
FIG. 3. Effect of FGF-2-soaked beads on limb differentiation in
ovo. The control, untreated side in each panel is on the left, the
treated side on the right. (A) FGF-2-coated beads implanted at stage
21 induce shortened and thickened skeletal elements. PBS-soaked
(B) and anti-FGF-2-soaked beads (C) have no effect on limb devel-
opment. Arrows indicate the site of bead implantation. h, humerus;
r, radius; u, ulna; d, digits. Scale bar, 1 mm.
104 Moore et al.
© 2002 Elsevier Science (USA). All rights reserved.
FIG. 4. Blocking FGF-2 in CAM grafts of E10 cranial tissue results in a graded response. (A–C) Implantation of a single anti-FGF-2-coated bead
causes a two- to threefold increase in graft size (A, B) when compared with grafts that received PBS-soaked beads (C) (P 0.0005). (B) A proportion
of these grafts also shows a reduction in bone differentiation. (D) Implantation of three anti-FGF-2 beads blocks any further bone differentiation
beyond that already determined at the time of grafting. (E) Graft implanted with three PBS-soaked beads for comparison. It should be noted that
in (A), (B), and (D) the changes are global throughout the graft and are not restricted to the site of bead implantation, as indicated by the arrows.
(F) Preblocking anti-FGF-2 with its ligand FGF-2 (as described in Materials and Methods) prevents anti-FGF-2-mediated growth and maintains
osteogenic differentiation (compare with A, B, and D). (G) This graph shows the percentage of CAM grafts with reduced bone differentiation (pink
bars) as opposed to normal bone formation (blue bars) and the average surface area of grafts in each treatment (line). The response is broadly
dependent on the number of beads implanted. Statistical analysis using the G-test for independence reveals significant differences in the
proportion of grafts which differentiate normally following implantation with three anti-FGF-2 beads compared with those implanted with one
or three PBS beads, beads soaked in rabbit serum, and single preblocked anti-FGF-2 beads (P  0.001). This difference is not seen between grafts
implanted with different numbers of PBS-coated beads. Sample size per experimental category ranged between 15 and 25 grafts. Scale bar, 1 mm.
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affected (Fig. 3A). This almost certainly reflects the fact that,
at the stage of bead implantation, the humerus, radius, and
ulna are differentiating, whereas the later-forming digital
structures are unaffected. Limbs implanted with PBS- or
anti-FGF-2 soaked beads developed in a manner which was
indistinguishable from the nonoperated contralateral side
(Figs. 3B and 3C). Measurements of length and width of
control and FGF-treated limb bones and statistical analysis of
the results (Table 1) corroborate the morphological observa-
tions. FGF-2 implanted limbs have significantly shorter and
wider limb elements than both control and antibody-treated
limbs. This finding confirms that implanted beads release
biologically active FGF-2. Thus, the lack of an effect of
FGF-2-soaked beads on cranial skeletogenesis in CAM grafts
appears to reflect a lack of response to exogenous FGF-2 by
cranial tissues.
Blocking Endogenous FGF-2 Elicits Mesenchymal
Growth
We considered the possibility that cranial tissues do not
respond to exogenous FGF-2 because it is already present in
the tissue at a high concentration. To test this idea, we
studied the effect of blocking the activity of endogenous
FGF-2 in CAM grafts using agarose beads soaked in a
neutralising antibody. Implantation of a single anti-FGF-2
bead in E10 grafts left to develop for 6 days caused a massive
and symmetrical increase in the size of the grafts (P 
0.0005; Figs. 4A and 4B, compare with Fig. 4C at the same
magnification). Bone formation appears normal (Fig. 4A) or
reduced (Fig. 4B) in the grafts (in terms of patterning and
size of the skeletal elements), and it seems likely that the
increase in graft size can be attributed to an increase in
proliferation of mesenchymal cells. To examine this fur-
ther, representative grafts from each category were embed-
ded, sectioned, and stained for PCNA protein, which is
normally localised to the nuclei of proliferating cells. In
grafts with one anti-FGF-2 bead, almost all mesenchymal
cells are proliferating (Fig. 5A), whereas in control (PBS
bead) grafts there is a low level of proliferation in the
mesenchyme (Fig. 5C) but a higher level in developing bone,
cartilage, and feather germs (Fig. 5F and data not shown). To
quantitatively assess the changes in proliferation, the num-
ber of positive and negative cell nuclei was counted in
representative sections (see Materials and Methods), and
the differences were analysed statistically. There is a sig-
nificant difference between the number of proliferative
mesenchymal cells in control grafts and grafts treated with
one anti-FGF-2 bead (P  0.001) (Fig. 5G).
Implantation of Multiple Anti-FGF-2-Coated Beads
Blocks Both Cell Proliferation and Further
Osteogenic Differentiation
When two to three antibody loaded beads were im-
planted, in order to block a greater proportion of endoge-
nous FGF-2, a different response was observed (Fig. 4D). The
grafts were similar in size to those which were implanted
with three PBS beads (Fig. 4E), but progression of bone
differentiation was completely blocked beyond the time of
grafting. Although some frontal bone formed (Fig. 4D), it is
likely that these progenitor cells were already committed to
differentiate before bead implantation. Occipital cartilages
are already formed at the time of grafting, which explains
why these structures are unaffected (compare with Fig. 1B).
Frontal bone differentiation is normally initiated at the
anterior region of the skull, lateral to the eye, and proceeds
caudally. It is the posterior region of the frontal bone that
fails to form in these grafts. The effect of anti-FGF-2 beads
on skeletal development of the graft, as well as that on graft
growth, is not localised around the bead implantation site
(Fig. 4D), but appears to be widespread within the graft.
Detection of PCNA protein in sections of these grafts
suggests that proliferation, in addition to differentiation, is
blocked in these tissues (Figs. 5B and 5E). Very little
mesenchymal proliferation is observed and, in addition,
cells that would normally be dividing at this stage, such as
epidermis, bone, and cartilage, are not PCNA-positive.
Statistical analysis reveals that, in all tissues examined,
there is a significant difference in the level of cell prolifera-
tion between controls and grafts implanted with three
anti-FGF-2 loaded beads (P  0.001) and between the latter
and grafts implanted with a single anti-FGF-2 bead (P 
0.001) (Fig. 5G).
To confirm that the antibody against FGF-2 was blocking
FGF-2 specifically, agarose beads were soaked in a mixture
of FGF-2 and anti-FGF-2 and implanted into cranial grafts
(Fig. 4F). These grafts were of equivalent size and showed
typical bone differentiation when compared with control
grafts (Figs. 4C and 4E), indicating that preblocking anti-
FGF-2 with its ligand prevents any phenotypic changes. In
addition, substituting FGF or preimmune serum for anti-
FGF-2 had no effect on graft size or osteogenic differentia-
tion (Fig. 4G).
The data from both these experiments are graphically
displayed in Fig. 4G and indicate that there is some overlap
between the extent of skeletal development seen with each
treatment. The increase in size is significantly higher in
treated grafts as described above.
Different Numbers of Beads Release Different
Concentrations of Antibody Both in Vivo
and in Vitro
Since it appeared that the addition of more beads in-
creased the amount of anti-FGF-2 delivered to the tissue,
we decided to analyse the release dynamics both qualita-
tively and quantitatively. Using a whole-mount immuno-
staining protocol, the amount of antibody released and the
extent to which it had diffused over time were measured in
vivo (Fig. 6). At all time points analysed, there appeared to
be a higher concentration of anti-FGF-2 detectable in grafts
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implanted with three beads than in those implanted with a
single bead. In addition, the distance over which the anti-
body diffused was greater in the former category (compare
Figs. 6A, 6C, 6E, and 6G with Figs. 6B, 6D, 6F, and 6H). By
12 h after implantation, anti-FGF-2 was detectable within
at least two-thirds of the graft (Fig. 6F), explaining why the
observed effects on proliferation and differentiation are
global. By 24 h, we were unable to detect protein in grafts
implanted with a single anti-FGF-2 bead, whereas distinct
staining could still be seen in grafts implanted with three
beads (compare Fig. 6G and Fig. 6H). When assessing
antibody specificity by preblocking anti-FGF-2 with FGF-2,
it was important to ensure that FGF-2 was not replacing
anti-FGF-2 in agarose beads. Whole-mount immunohisto-
chemistry on such grafts indicates that anti-FGF-2 is detect-
able but remains localised to the agarose bead 2 h after
implantation (Fig. 6J).
To confirm the in vivo data showing that implantation of
three beads resulted in higher levels of blocking antibody in
the CAM graft than implantation of one bead, we used an
ELISA assay to quantify the level of anti-FGF-2 released
from different numbers of beads in solution. There is clearly
an increased concentration of anti-FGF-2 released in the
first hour from three beads compared with one bead (Fig. 7).
Although by 3 h of incubation the level of antibody released
from three beads has dropped, it remains higher than that
elicited from one bead.
FGF-2, FGFR1, and FGFR2 Proteins Are Found in
the Developing Skull throughout Development
To confirm that FGF-2 and its receptors are present in
cranial tissues during the developmental window used in
these experiments, we analysed their expression by immu-
nohistochemistry. Figure 8 depicts the pattern of protein
expression in transverse sections of embryonic chick skull
at 10 and 13 days of development. FGF-2, FGFR1, and
FGFR2 show similar patterns of expression and are particu-
larly strongly localised in the brain, choroid plexus (Fig. 8B),
periosteum, cranial sutures (Figs. 8A, 8C, 8E–8G), and
developing cartilage (data not shown). The concentration of
ligand and receptor protein in cranial sutures increases and
becomes more restricted by 13 days (compare Figs. 8A and
8E with Figs. 8C, 8F, and 8G). These data are supported by
Western blot analyses (data not shown) and provide evi-
dence that, within the normal developing skull, both ligand
and receptors display spatial and temporal expression pat-
terns consistent with their perceived roles in the regulation
of suture patency and osteogenesis.
DISCUSSION
A number of studies have provided evidence for the role
of FGF-2 in cranial skeletogenesis. For example, ectopic
expression of the early bone marker osteopontin and down-
regulation of Fgfr2 have been induced by FGF-2 beads in
mouse crania (Iseki et al., 1997, 1999). In addition, dural cell
cultures derived from the fusing frontal suture in mice
express significantly greater levels of FGF-2 (Greenwald et
al., 2000). Recent work has demonstrated that the neural
crest precursors of the skeletogenic tissues in the embry-
onic head express FGFRs and, when cultured, are capable of
responding to FGF-2 in a concentration-dependent manner
(Sarkar et al., 2001). The present work complements these
findings by showing that the progeny of cranial neural crest
cells in vivo respond to inactivation of endogenous FGF-2
by displaying a switch from skeletogenetic differentiation
to proliferation. In vivo responses appear to be determined
by the degree of inactivation of endogenous FGF-2, and
seem at least crudely concentration-dependent. Delivery of
the neutralising antibody by beads was measured by ELISA
and indicates that increasing the number of implanted
beads can achieve a two- to threefold increase in the
concentration of antibody delivered.
Implantation of a single antibody-coated bead switched
mesenchymal cells into a proliferative mode and produced
massively overgrown grafts, although osteogenesis re-
mained relatively normal. This effect was manifest over the
entire graft and not locally around the bead implantation
site, also illustrated by the lack of a PCNA gradient around
the bead, and consistent with the fact that the antibody
rapidly diffuses throughout a wide area of the graft (several
millimetres in size). Interestingly, in a few experiments
where CAM grafts were implanted with a single bead
soaked in 5 mg/ml anti-FGF-2, the resulting grafts were
even larger than those implanted with a single bead soaked
in 10 mg/ml anti-FGF-2 (data not shown), indicating that
blocking endogenous FGF-2 to a lesser degree provokes a
greater proliferative response.
However, when more endogenous ligand is blocked, by
implanting multiple beads soaked in 10 mg/ml anti-FGF-2,
further bone differentiation is halted completely and mes-
enchymal cells become quiescent, displaying neither pro-
liferation nor differentiation. The concentration of anti-
FGF-2 used in these experiments is quite high, and it is
therefore not surprising that the addition of more beads has
such a profound effect, particularly since the majority of
FGF-2 activity is likely to be blocked.
It has yet to be established whether the primary effect of
high levels of FGF-2 in skeletogenic tissues is to induce
skeletogenic differentiation, with low proliferative activity
being a consequence of cells entering the differentiation
programme, or whether it is to inhibit proliferation, and as
a result favour differentiation. However, in cultures of
neural crest cells exposed to high concentrations of FGF-2,
the cells at the periphery of the differentiating cartilage
nodule are proliferating (Sarkar et al., 2001), providing more
support for the former rather than the latter hypothesis.
The concentration-dependent response to FGF-2 observed
107FGF-2 and Cranial Osteogenesis
© 2002 Elsevier Science (USA). All rights reserved.
FIG. 5. The level of cell proliferation in grafted tissue is dependent on the endogenous level of FGF-2. (A–F) Detection of PCNA in CAM
grafts at the same stage as those described in Fig. 4. Positive cell nuclei are stained brown, and negative nuclei are blue. (A, D) Sections of
grafts implanted with one anti-FGF-2-coated bead; (B, E) three anti-FGF-2-coated beads; (C, F) one PBS control bead. (A–C) Representative
fields of mesenchyme taken from the centre of the graft. In (A), almost all nuclei are proliferating, whereas, in (B), the level of proliferation
is low. (C) The background level of cell proliferation typically seen in grafted cranial tissue. (D–F) Pattern of PCNA expression in developing
frontal bones confirms that cell proliferation is stimulated if FGF-2 is blocked partially by insertion of a single anti-FGF-2 bead (D) and
arrested when more anti-FGF-2 beads are present (E). (F) In control grafts, cell proliferation occurs in the periosteum at the periphery of
differentiating bones. (G) Quantitative analysis of these data reveals a massive increase in mesenchymal cell proliferation (P  0.001) and
a moderate increase in osteogenic and epidermal proliferation after implantation of a single anti-FGF-2 bead, whereas cell proliferation in
all these tissues is reduced below background levels when three anti-FGF-2 beads are inserted (P  0.001). In all cases, the differences are
statistically significant. The PCNA index denotes the percentage of cells within a field which stain positive for PCNA and hence are
proliferating. These differences have been analysed statistically by using the G-test for independence. Cell nuclei were counted in 5 fields
in each of 5 sections from 5 grafts per treatment, totalling 25 counts per graft. b, bead. Scale bar, 50 m; except in (D), 125 m.
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FIG. 6. Whole-mount immunohistochemistry of E10 CAM grafts, left to develop for 6 days, to detect the release of anti-FGF-2 from
different numbers of implanted beads over time. Grafts were implanted with a single bead coated in anti-FGF-2 (A, C, E, G) or with three
anti-FGF-2 beads (B, D, F, H). Control grafts were implanted either with a single PBS-coated bead (I) or with three PBS beads (not shown).
Grafts were fixed after 15 min (A, B), 6 h (C, D), 12 h (E, F), or 24 h (G–I). (A, B) The level of anti-FGF-2 released from one bead (A) is clearly
lower than in grafts implanted with three anti-FGF-2 beads (B) Fifteen minutes after implantation. This remains the case for all other time
points analysed (compare C with D and E with F). By 12 h after implantation, anti-FGF-2 is barely detectable in grafts that received a single
bead (E) and appears to be absent by 24 h (G). In contrast, grafts implanted with three beads exhibit detectable anti-FGF-2 at both 12 (F) and
24 h (H). In addition, the area over which anti-FGF-2 diffuses appears to be greater in grafts implanted with three beads than in those
implanted with a single bead. The specificity of anti-FGF-2 was tested by soaking beads in FGF-2 and anti-FGF-2 (J). In these grafts after 2 h,
anti-FGF-2 could be detected but remained localised to the bead. Control grafts at all stages show no staining (I). The site of implanted beads
is marked with arrows. Scale bar, 1 mm.
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in the cranial vault complements the effect seen when
neural crest cells are cultured in the presence of increas-
ing levels of exogenous FGF-2. At low levels of FGF-2,
neural crest cells proliferate in vitro, whereas at higher
levels the cells initially differentiate into cartilage and
later form bone. There appears to be an initial period of
24 – 48 h during which neural crest cells must be continu-
ously exposed to FGF-2 for skeletogenesis to occur
(Sarkar et al., 2001). It may be, therefore, that, in addition
to the concentration of antibody delivered, the length of
time that endogenous FGF-2 is blocked in that region is
also a critical factor. In support of this idea is our finding
that implantation of an increased number of beads results
in prolongation of the time during which antibody re-
mains detectable.
Collectively, our results and those of Iseki et al. (1997,
1999) and Sarkar et al. (2001) are consistent with the idea
that the mutations in FGFR1, FGFR2, and FGFR3 that
cause craniosynostosis are activating mutations, confer-
ring ligand independence on the receptor in question and
leading to an uncontrolled upregulation of intracellular
signalling.
Are the Endogenous Levels of FGF-2 Rate Limiting
in Craniofacial Tissues as with the Limb?
The failure of additional exogenous FGF-2 (at levels of
1–10 mg/ml) to produce any discernible effect on skull form
or pattern was quite surprising. This is in sharp contrast to
the effects found in the limb where exogenous FGF-2 and
FGF-4, placed in the flank, can induce ectopic limb buds
(Cohn et al., 1995). We therefore assayed the biological
activity of FGF-2-coated beads by implanting them into
early limb buds. This demonstrated that the beads do
indeed release FGF-2 which is active and capable of altering
the development of limb skeletal elements that grow
thicker but shorter than controls. Our results are consistent
with shortening and flattening of the long bones and mod-
erate macrocephaly observed in transgenic mice overex-
pressing FGF-2 (Coffin et al., 1995). The introduction of
neutralising antibody into the limb produced no effect, in
contrast to its effect on the cranial vault, where the anti-
FGF-2-soaked beads elicited a profound response.
These tissue-specific differences may reflect lineage dif-
ferences, in that limb mesenchyme is predominantly me-
sodermal in origin (e.g., Hinchliffe and Johnson, 1980),
whereas that of the cranial vault is predominantly neural
crest-derived (Couly et al., 1993). However, the reasons are
likely to be complicated by factors of ligand redundancy,
tissue-specific differences in isoform expression, and per-
haps by the fact that the rate-limiting factors may be
different in each tissue. Thus, in the limb mesenchyme, it
is ligand, not receptor, availability that may be rate limit-
ing; addition of extra ligand would therefore be predicted to
have morphogenetic consequences. In craniofacial tissues, a
situation of superfluous ligand and limited receptor avail-
ability might not be expected to display a response to
additional exogenous ligand but will do so when endoge-
nous levels fall below a critical threshold level. This hy-
pothesis is supported in work by Iseki et al. (1997), in which
changes in local osteopontin and FGFR2 expression could
only be induced by the application of FGF-2 at very high
doses (400 mg/ml). Hence, an extremely large increase in
the local concentration of FGF-2 does not provoke morpho-
logical changes and explains why, when FGF-2 availability
is reduced (as demonstrated in this study), there is a
profound effect on growth and differentiation. A recent
study showing that inactivation of Fgf2 in mice results in a
decrease in endochondral bone mass and bone formation in
vivo (Montero et al., 2000) further supports this hypothesis.
Addition of recombinant FGF-2 back to cultures of calvarial
osteoblasts taken from these FGF-2/ mice induced a
mitogenic response (although it was not completely re-
stored). This indicates that the addition of FGF-2 back to
cells which have a low endogenous level of FGF-2 is able
induce a proliferative response. This supports the sugges-
tion that, normally, levels of FGF-2 are high in the devel-
oping skull and therefore, as shown in this study, addition
FIG. 7. Concentration of anti-FGF-2 released by different num-
bers of beads as measured by ELISA. At all time points, the
concentration of anti-FGF-2 released from three beads (soaked in 10
mg/ml) was higher than that released from a single bead. Single
beads soaked in lower concentrations of anti-FGF-2 (1 mg/ml and
100 g/ml) released very low detectable levels of antibody. Histo-
grams represent mean values (SEM) from at least three experi-
ments.
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of exogenous FGF-2 to cranial tissues may not have an
effect.
It has been reported that the CAM is itself a source of
FGF-2 (Flamme et al., 1991; Ribatti et al., 1995). It is
therefore a possibility that the presence of endogenous
FGF-2 in the CAM might influence morphological changes
in grafted cranial tissue. However, we do not believe that
CAM-derived FGF-2 affected graft differentiation for two
reasons. First, work by Ribatti et al. (1995) has shown that
the levels of FGF-2 produced by the CAM between 10 and
14 days of development reached a maximum of 183 ng/g of
wet tissue. This is significantly lower than the lowest
concentration of FGF-2 in which beads were soaked prior to
implantation. Second, if FGF-2 derived from the CAM
affected cranial differentiation, control grafts would be
similarly affected, and, as shown in Fig. 2, they exhibit
normal patterns of differentiation.
FGF–FGFR Interactions Are Complex and May
Explain Changes in Phenotype
It is interesting to note that, although many craniosyn-
ostosis syndromes such as Apert and Pfeiffer are accompa-
nied by varying degrees of limb defects, Crouzon syndrome
is not. However, it has been reported that the same base pair
mutation in FGFR2 can cause both Crouzon and Pfeiffer
syndromes (Muenke and Schell, 1995). The mechanisms
involved are clearly complex and it is possible that only
subtle differences in the levels of FGF signalling have
profound effects on phenotype. The issue is further clouded
by the ability of FGFs to bind to more than one receptor,
probably with different affinities, and by the presence of
FGFR isoforms generated as a result of alternative splicing
(Green et al., 1996). These splice variants have different
ligand binding capabilities and expression patterns (Orr-
Urtreger et al., 1993; Delezoide et al., 1998; Chan and
Thorogood, 1999) and are often found in complementary
locations during craniofacial development. In addition,
each ligand is known to have several isoforms produced by
the use of alternative translation initiation sites, as well as
alternative splicing (Mason, 1994), and it is possible that
each will therefore have different receptor binding capabili-
ties. These various elements therefore may each play a role
in determining which mutations result in more severe
phenotypes.
Several studies have implicated the dura mater in the
control of sutural closure (Greenwald et al., 2000; Kim et
al., 1998; Levine et al., 1998). The culture of embryonic
calvaria without dura resulted in an increase in the level of
osteogenesis and more rapid sutural synostosis (Kim et al.,
1998). Other studies have suggested that this more rapid
closure will only occur at defined points during develop-
ment (between late fetal and early postnatal stages), and so
the dura mater, although not required for initial suture
formation, is essential for its patency (Opperman et al.,
1993). In rats and mice, paracrine signalling of TGF1 and
FGF-2 from dura to suture appears to correlate with sutural
fusion (Greenwald et al., 2000; Most et al., 1998). Sutural
morphogenesis and maintenance therefore seem to be regu-
lated by interactions between at least three tissue types:
cranial mesenchyme, differentiating calvarial bones, and
the dura mater.
FGF and FGFR Proteins Are Found in Developing
Cranial Tissues at the Time of Osteogenic
Differentiation
We have demonstrated the presence of FGF-2 at early
stages of differentiation within bone and at a higher level in
the periosteal layer that surrounds the bone. Interestingly,
while the highest concentration of FGF-2 is seen in differ-
entiating bone, there appears to be an increase in FGF-2
protein localised to the suture when compared with the rest
of the cranial mesenchyme. This may be driving these cells
to divide rather than differentiate, thereby preventing su-
tural closure. These expression data further suggest that the
level of FGF-2 in the developing skull determines the
phenotypic response. Therefore, at the lowest levels of
FGF-2 in cranial mesenchyme, neither proliferation nor
differentiation occurs. At higher levels of FGF-2, as ob-
served in the cranial suture, the primary response is cell
proliferation (see also Iseki et al., 1999). The highest levels
of FGF-2 are found in those areas undergoing osteogenic
differentiation. This gradient of expression partly explains
the differing phenotypic responses seen in this study when
endogenous FGF-2 is blocked to differing degrees.
We find FGFR1 and FGFR2 proteins in roughly the same
locations as previously reported in gene expression studies
(Iseki et al., 1997; Delezoide et al., 1998; Kim et al., 1998;
Chan and Thorogood, 1999). Receptors are expressed by the
periosteum, rather than in bone itself, suggesting a role in
osteogenesis rather than bone maintenance. It is important
to note that, at present, commercial antibodies are not
specific for particular splice variants or isoforms. It will be
interesting to determine the precise localisation of the
different splice variants when specific antibodies become
available.
CONCLUSIONS
We report a method for manipulating endogenous FGF
levels in embryonic tissues and demonstrate a
concentration-dependent response of cranial skeletal tis-
sues to reduced levels of FGF-2. Our findings provide an in
vivo experimental model by which we can analyse the
developmental mechanisms underlying normal sutural
growth and morphogenesis and understand the pathological
early closure of sutures seen clinically. It may be that, by
further manipulating the levels of other growth factors
implicated in cranial morphogenesis, we can readily shift
the balance between proliferation and skeletogenesis and
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hence obtain a clearer understanding of the mechanisms
involved in both normal and abnormal cranial differentia-
tion.
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